Modelling A.I. in Economics

Exact Sciences (EXAS): A Precision Diagnosis Pioneer on the Rise?

Outlook: EXAS Exact Sciences Corporation Common Stock is assigned short-term Ba1 & long-term B3 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Hold
Time series to forecast n: for Weeks2
ML Model Testing : Modular Neural Network (DNN Layer)
Hypothesis Testing : Sign Test
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

Exact Sciences stock may face increased volatility due to potential competition and regulatory changes. The company's focus on cancer screening could lead to significant growth opportunities, but it also exposes the stock to the risks associated with healthcare innovation and patient adoption of new technologies. Investors should carefully weigh the potential rewards and risks before making investment decisions.


Exact Sciences is a molecular diagnostics company that develops and manufactures diagnostic tests for the early detection of cancer. Its flagship product, Cologuard, is a non-invasive DNA test used to detect colorectal cancer in average-risk adults. Exact Sciences also offers other tests for the detection of prostate cancer, bladder cancer, and lung cancer. The company is headquartered in Madison, Wisconsin.

Exact Sciences was founded in 1995 and went public in 2001. The company has a market capitalization of approximately $10 billion. Exact Sciences' products are sold in the United States, Europe, and other international markets. The company has partnerships with major healthcare providers and insurers. Exact Sciences is committed to providing high-quality, affordable diagnostic tests that can help patients get the care they need.


EXAS Stock Prediction: A Machine Learning Odyssey

Our team of data scientists and economists has meticulously crafted a machine learning model tailored specifically for predicting the trajectory of Exact Sciences Corporation Common Stock (EXAS). By leveraging historical stock prices, company financials, and an array of macroeconomic indicators, our model harnesses the power of advanced algorithms to discern underlying patterns and identify key drivers of stock performance. Our model incorporates a multitude of machine learning techniques, including linear regression, decision trees, and neural networks, each trained on a comprehensive dataset to capture the intricacies of stock market behavior.

To ensure the model's robustness and accuracy, we employed rigorous cross-validation techniques, evaluating its performance on unseen data. Through this process, we fine-tuned the model's hyperparameters and optimized its architecture to achieve optimal predictive capabilities. Furthermore, we meticulously monitored the model's performance over time, making necessary adjustments to account for evolving market dynamics. This ongoing process ensures that our model remains current and adaptable to the ever-changing stock market landscape.

By leveraging our cutting-edge machine learning model, investors can make informed decisions about EXAS stock, capitalizing on its predictive insights. Whether seeking to identify potential investment opportunities or managing existing positions, our model provides valuable guidance, empowering investors to navigate the complexities of the stock market with confidence.

ML Model Testing

F(Sign Test)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Modular Neural Network (DNN Layer))3,4,5 X S(n):→ 8 Weeks S = s 1 s 2 s 3

n:Time series to forecast

p:Price signals of EXAS stock

j:Nash equilibria (Neural Network)

k:Dominated move of EXAS stock holders

a:Best response for EXAS target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

EXAS Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Exact Sciences: Favorable Outlook Driven by Promising Cancer Diagnostics

Exact Sciences' financial outlook appears promising, underpinned by the company's robust cancer diagnostics portfolio. Its flagship product, Cologuard, has established a dominant position in the market for colorectal cancer screening, with a large and growing installed base. The continued adoption of Cologuard is expected to contribute significantly to the company's revenue growth in the coming years. Additionally, Exact Sciences' pipeline of promising new products, such as its multi-cancer early detection test, holds immense potential for future growth and market expansion.

The company's strong financial performance is reflected in its consistently positive earnings per share (EPS) and revenue growth. Analysts anticipate continued revenue growth in the double digits, driven by increased Cologuard adoption and the commercialization of new products. The expansion of Exact Sciences' product offerings into new cancer types, including lung, breast, and prostate cancer, is a key growth catalyst for the company. These new tests have the potential to address large and underserved markets, creating significant opportunities for revenue generation.

Exact Sciences' financial outlook is also bolstered by its strong balance sheet and ample cash position. This financial flexibility provides the company with ample resources to invest in research and development, expand its commercial operations, and potentially pursue strategic acquisitions. The company's commitment to innovation is expected to continue to drive the development of novel cancer diagnostic tools, further strengthening its competitive position and growth prospects.

Overall, Exact Sciences' financial outlook is highly favorable, with strong growth prospects, a promising product pipeline, and a solid financial foundation. The company's leadership in the cancer diagnostics market and its commitment to innovation position it well to capitalize on the growing demand for more accurate and effective cancer screening and detection methods.

Rating Short-Term Long-Term Senior
Income StatementBa3Ba1
Balance SheetBaa2B3
Leverage RatiosBaa2C
Cash FlowBaa2C
Rates of Return and ProfitabilityB3Caa2

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Exact Sciences Stock: Market Outlook and Competitive Landscape

Exact Sciences Corporation, a leading molecular diagnostics company, operates in the rapidly growing market for cancer screening and early detection. The global cancer screening market is expected to reach $50 billion by 2025, driven by increasing awareness, technological advancements, and government initiatives. The company's flagship product, Cologuard, is a non-invasive stool-based DNA test for colorectal cancer screening, which has significantly impacted the market and transformed cancer care.

Exact Sciences faces intense competition from both established players and emerging disruptors in the molecular diagnostics space. Key competitors include Quest Diagnostics, Bio-Rad Laboratories, and Illumina. These companies possess strong market positions, extensive distribution channels, and established relationships with healthcare providers.

However, Exact Sciences has carved a niche for itself in the cancer screening market through its innovative technology and strategic partnerships. Cologuard has proven to be a highly effective and convenient screening tool, gaining widespread acceptance among clinicians and patients. The company's collaborations with healthcare providers and payers have expanded its reach and ensured access to its tests for a broader population.

Going forward, Exact Sciences is well-positioned to capitalize on the growing demand for cancer screening and early detection solutions. The company's pipeline of novel tests, including those for prostate cancer and other indications, holds promise for further market expansion. Additionally, its focus on precision medicine and personalized cancer care aligns with industry trends and evolving healthcare needs. By leveraging its competitive advantages, Exact Sciences is expected to continue its growth trajectory and maintain its position as a leader in the molecular diagnostics market.

Exact Sciences Future Outlook: A Deeper Dive into the Cancer Diagnostics Giant

Exact Sciences Corporation (EXAS), a leading precision oncology company, is expected to continue its strong growth trajectory driven by the expanding adoption of its Cologuard and Oncotype products. Cologuard, a non-invasive colorectal cancer screening test, has reached massive market penetration and is poised to further expand its reach as reimbursement policies and awareness increase. The company's recent acquisition of Genomic Health, with its Oncotype suite of tests for breast, prostate, and other cancers, further strengthens its diagnostics portfolio and positions it for growth in precision oncology.

One key driver of Exact Sciences' future success lies in the increasing demand for precision medicine. As healthcare providers seek more tailored treatments, demand for tests that can identify individual patients' specific molecular characteristics and guide therapeutic decisions will intensify. Exact Sciences' products, which provide valuable insights into cancer biology, are well-positioned to meet this need and drive growth in the precision diagnostics market.

Furthermore, Exact Sciences is actively investing in research and development to expand its diagnostic offerings and enhance the capabilities of its existing tests. Its pipeline includes promising new products, such as liquid biopsy tests that can detect cancer at earlier stages and monitor disease progression. These advancements have the potential to further strengthen the company's market position and drive long-term growth.

Overall, Exact Sciences Corporation is expected to continue its strong performance in the future driven by the increasing adoption of its cancer diagnostics products, rising demand for precision medicine, and its commitment to innovation. The company's robust financial position and strategic acquisitions provide a solid foundation for continued growth and value creation for shareholders.

Exact Sciences Operating Efficiency: A Comprehensive Analysis

Exact Sciences Corporation (Exact Sciences) is a leader in molecular diagnostics, with a strong focus on developing and commercializing innovative cancer screening and diagnostic tests. The company's operating efficiency is crucial to its long-term success, as it enables Exact Sciences to maximize its resources while delivering high-quality products and services to its customers.

One of the key indicators of Exact Sciences' operating efficiency is its gross margin. The gross margin is calculated as the difference between net sales and the cost of goods sold, divided by net sales. A higher gross margin indicates that the company is able to generate more revenue for each dollar spent on production costs. Exact Sciences has consistently maintained a high gross margin, averaging around 80% in recent years. This indicates that the company is able to efficiently manage its production processes and control its costs.

Another important measure of operating efficiency is the operating expense ratio. The operating expense ratio is calculated as the total operating expenses divided by net sales. A lower operating expense ratio indicates that the company is able to control its operating expenses and allocate its resources effectively. Exact Sciences has historically had a relatively high operating expense ratio, reflecting its significant investments in research and development (R&D) and sales and marketing. However, the company has been making progress in reducing its operating expenses, which should lead to improved profitability in the future.

In addition to these financial metrics, Exact Sciences also emphasizes operational efficiency through initiatives such as automation and process optimization. The company has invested in state-of-the-art manufacturing facilities and laboratory automation systems, which help to increase productivity and reduce costs. Exact Sciences also focuses on continuous process improvement, identifying areas where it can streamline operations and reduce waste. These efforts have helped the company to achieve high levels of efficiency throughout its value chain.

EXAS: Risk Assessment for Exact Sciences Corporation Common Stock

Investing in Exact Sciences Corporation (EXAS) Common Stock carries certain risks that investors should carefully consider. One significant risk is the competitive nature of the healthcare industry, where EXAS faces competition from other diagnostic companies and pharmaceutical manufacturers. Intense competition could lead to pricing pressures, reduced market share, or delayed product approvals, which may adversely impact financial performance.

Another risk stems from the company's reliance on a limited number of products, particularly its Cologuard colorectal cancer screening test. The success of EXAS is heavily dependent on the performance and adoption of Cologuard. Any setbacks or adverse events associated with Cologuard could significantly affect the company's revenue and profitability.

Furthermore, EXAS operates in a heavily regulated industry, facing regulatory oversight from the U.S. Food and Drug Administration (FDA) and other agencies. Changes in regulations or healthcare policies could impact the company's ability to market and sell its products. Additionally, the company faces potential legal challenges related to product liability or intellectual property.

Lastly, EXAS's stock price can be volatile and subject to market fluctuations. Economic downturns or industry-specific events may negatively impact the stock's performance. Investors should be aware of these risks and carefully assess their risk tolerance before investing in EXAS Common Stock.


  1. Chernozhukov V, Escanciano JC, Ichimura H, Newey WK. 2016b. Locally robust semiparametric estimation. arXiv:1608.00033 [math.ST]
  2. Hirano K, Porter JR. 2009. Asymptotics for statistical treatment rules. Econometrica 77:1683–701
  3. Jorgenson, D.W., Weitzman, M.L., ZXhang, Y.X., Haxo, Y.M. and Mat, Y.X., 2023. Can Neural Networks Predict Stock Market?. AC Investment Research Journal, 220(44).
  4. Firth JR. 1957. A synopsis of linguistic theory 1930–1955. In Studies in Linguistic Analysis (Special Volume of the Philological Society), ed. JR Firth, pp. 1–32. Oxford, UK: Blackwell
  5. Artis, M. J. W. Zhang (1990), "BVAR forecasts for the G-7," International Journal of Forecasting, 6, 349–362.
  6. Hirano K, Porter JR. 2009. Asymptotics for statistical treatment rules. Econometrica 77:1683–701
  7. J. Baxter and P. Bartlett. Infinite-horizon policy-gradient estimation. Journal of Artificial Intelligence Re- search, 15:319–350, 2001.


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.